NCT04333472 - Piclidenoson for Treatment of COVID-19 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 6, 2021

Primary Completion Date

March 6, 2022

Study Completion Date

April 21, 2022

Conditions

COVID-19Coronavirus Infection

Interventions

DRUG

Piclidenoson

Piclidenoson 2 mg orally every 12 hours for up to 28 days

DRUG

Placebo

Placebo orally every 12 hours for up to 28 days

Trial Locations (6)

II Multiprofile Hospital for Active Treatment - Sofia EAD, Sofia

IV Multiprofile Hospital for Active Treatment - Sofia EAD, Sofia

Hadassah Medical Center, Jerusalem

Shaare Zedek Medical Center, Jerusalem

"Clinical Hospital for Infectious Diseases St. Parascheva Iasi", Iași

"Sfantul Ioan cel Nou County Emergency Hospital Suceava", Suceava